Unjoni Ewropea - Malti - EMA (European Medicines Agency)

3m health care limited - rivastigmine - marda ta 'alzheimer - psychoanaleptics, , anticholinesterases - trattament sintomatiku ta 'dimenzja ta' alzheimer ħafifa għal moderatament gravi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , terapija ta 'kumbinazzjoni tripla) bħala żieda mad-dieta u l-eżerċizzju f'pazjenti mhux ikkontrollati adegwatament fuq id-doża massima ttollerata ta' metformin u sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

phoenix labs unlimited company - zoledronic acid, zoledronic acid monohydrate - cancer; fractures, bone - drogi għat-trattament ta 'mard tal-għadam - prevenzjoni ta 'problemi skeletrali (ksur patoloġiku, kompressjoni tas-sinsla, radjazzjoni jew kirurġija fl-għadam, jew l-iperkalċemja kkawżata minn tumur) f'pazjenti b'kanċer avvanzat li jinvolvi l-għadam;it-trattament ta'iperkalċemja kkawżata minn tumur (tih);prevenzjoni ta' problemi skeletrali (ksur patoloġiku, kompressjoni tas-sinsla, radjazzjoni jew kirurġija fl-għadam, jew l-iperkalċemja kkawżata minn tumur) f'pazjenti b'kanċer avvanzat li jinvolvi l-għadam;it-trattament ta'iperkalċemja kkawżata minn tumur (tih);prevenzjoni ta ' problemi skeletrali (ksur patoloġiku, kompressjoni tas-sinsla, ir-radjazzjoni jew kirurġija fl-għadam, jew l-iperkalċemja kkawżata minn tumur) f'pazjenti adulti b'kanċer avvanzat li jinvolvi l-għadam;il-kura ta ' pazjenti adulti b'iperkalċemja kkawżata minn tumur (tih).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - fibrożi ċistika - prodotti oħra tas-sistema respiratorja - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - fibrożi ċistika - prodotti oħra tas-sistema respiratorja - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - nateglinide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - nateglinide huwa indikat għal terapija kombinata b'metformin f'pazjenti dijabetiċi tat-tip-2 li mhumiex ikkontrollati b'mod adegwat minkejja doża massima ta 'metformin ittollerata waħedha.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - siponimod-aċidu fumariku - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosuppressanti selettivi - mayzent huwa indikat għall-kura ta ' pazjenti adulti bi sklerożi multipla progressiva sekondarja (spms), bil-marda attiva muri mill-irkadar jew l-immaġini tal-karatteristiċi ta'l-attività infjammatorja.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

lantheus eu limited - perflutren - ekokardjografija - midja ta 'kuntrast - dan il-prodott mediċinali huwa għal użu dijanjostiku biss. luminity huwa ultrasound tal-kuntrast li jtejbu l-aġent għall-użu f'pazjenti li mhux l-ekokardjografija b'kuntrast kienet subottimali (subottimali hija kkunsidrata li tindika li mill-inqas tnejn mis-sitt segmenti fir-4 - jew il-2-chamber view tal-ventrikoli tal-fruntiera kienu ma setgħu jkunu evalwati) u li jkunu ssuspettati jew stabbilita mard tal-arterji koronarji, sabiex jipprovdi opacification tal-qalb awli u t-titjib tal-ventrikolu tax-xellug endocardial-delineazzjoni tal-fruntiera kemm fil-mistrieħ u stress.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - preparazzjonijiet antianemiċi - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - telbivudine - epatite b, kronika - inibituri nucleoside u nucleotide reverse transcriptase - sebivo huwa indikat għall-it-trattament ta ' kronika epatite b fil-pazjenti adulti b ' mard tal-fwied kompensat u evidenza ta ' replikazzjoni virali, b'persistenza elevati tas-serum aminotransferażi ta ' l alanina (alt) livelli u istoloġiċi evidenza ta ' infjammazzjoni attiva u/jew fibrosis. il-bidu ta 'sebivo it-trattament għandu jiġi kkunsidrat biss meta l-użu ta' sustanza antivirali alternattiva bl-ogħla ġenetiċi barriera għall-reżistenza mhix disponibbli jew ikun xieraq.